Pharmaceutical companies

Patient stratification and prevention of adverse side effects are rapidly becoming as important as traditional properties of therapeutics like efficacy, pharmacology and toxicity. Skyline is your partner of choice to develop signature-based tests to identify patient groups with favorable response profiles. Development of these crucial companion diagnostics can start as early as in the preclinical stage and may extend from phase I into phase IV clinical research.

Collaboration

Skyline’s extensive experience with all stages of diagnostics development ensures selection of the patient groups of choice, adding significant value to compounds, patented or generic.

We prefer to collaborate in risk- and cost-sharing co-developments, but other deal models are open for discussion.

The AMLprofiler for clinical research

The AMLprofiler serves as an excellent tool for standardizing AML diagnostics in a multi-site clinical trial. Improved classification of patients by means of the AMLprofiler offers the opportunity to assign drug responses or adverse side effects to specific patient groups. Contact us to discuss your options.